APOGEE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54 USD | +2.41% |
|
+3.41% | +93.27% |
| May. 13 | Apogee Therapeutics' Q1 Net Loss Widens | MT |
| May. 13 | Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.16B |
|---|---|---|---|---|---|
| Net income 2024 * | -150M | Net income 2025 * | -201M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 273M | Net cash position 2025 * | 415M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-20
x | P/E ratio 2025 * |
-16.7
x | Employees | 91 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.41% | ||
| 1 week | +3.41% | ||
| Current month | +7.36% | ||
| 1 month | -1.91% | ||
| 3 months | +53.76% | ||
| 6 months | +215.60% | ||
| Current year | +93.27% |
1 week
50.81
56.10
1 month
43.6156.10
Current year
27.0572.29
1 year
14.1972.29
3 years
14.1972.29
5 years
14.1972.29
10 years
14.1972.29
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 54 | +2.41% | 1,776,538 |
| 24-05-13 | 52.73 | -0.92% | 296,291 |
| 24-05-10 | 53.22 | +0.57% | 211,163 |
| 24-05-09 | 52.92 | +3.24% | 185,118 |
| 24-05-08 | 51.26 | -1.84% | 181,945 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotes
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
54
USD
Average target price
84.83
USD
Spread / Average Target
+57.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +93.27% | 3.16B | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +43.45% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- APGE Stock
